Literature DB >> 11425925

The cost of delaying treatment in multiple sclerosis: what is lost is not regained.

S R Schwid, C T Bever.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11425925     DOI： 10.1212/wnl.56.12.1620

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Disease modifying treatment in multiple sclerosis.

Authors:  G N Fuller; I Bone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

2.  The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region.

Authors:  Chiara de Waure; Francesco Di Nardo; Walter Mazzucco; Darko Nedovic; Mario Alberto Battaglia; Vincenzo Busillo; Walter Di Iorio; Antonio Gallo; Roberta Lanzillo; Emilio Lombardi; Giorgia Teresa Maniscalco; Giuseppe Orefice; Maria Petracca; Felice Romano; Leonardo Sinisi; Anna Pia Spadera; Daniele Spitaleri; Pasquale Vivo; Walter Ricciardi
Journal:  Neurol Sci       Date:  2015-10-06       Impact factor: 3.307

3.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

4.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

5.  Cognitive impairment in probable multiple sclerosis.

Authors:  A Achiron; Y Barak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

Review 6.  Interferon-beta treatment for multiple sclerosis.

Authors:  Robert A Bermel; Richard A Rudick
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 7.  Improving MS patient care.

Authors:  Peter Rieckmann
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 8.  Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Authors:  Thomas Berger; Irina Elovaara; Sten Fredrikson; Chris McGuigan; Lucia Moiola; Kjell-Morten Myhr; Celia Oreja-Guevara; Igor Stoliarov; Uwe K Zettl
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

Review 9.  Multiple sclerosis in the Arabian Gulf countries: a consensus statement.

Authors:  Saeed Bohlega; Jihad Inshasi; Abdel Rahman Al Tahan; Abu Bakr Madani; Hussien Qahtani; Peter Rieckmann
Journal:  J Neurol       Date:  2013-03-17       Impact factor: 4.849
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.